admin • June 6, 2022
Cardiac implantable device infections

The HCMA participated in an American Heart Association summit of more than 40 health care professionals to bridge gaps in awareness, detection, and appropriate treatment of cardiac implantable electronic device (CIED) infections.


As many as one in 20 patients with a CIED, such as a pacemaker or implantable defibrillator, develops an infection within three years of implantation. Despite current guidelines, only one in five patients with a CIED infection undergoes timely extraction – the most appropriate treatment option. Early extraction is associated with a 41% lower risk of death. Female and Black patients are even less likely to undergo this lifesaving procedure.

During the summit, participants – including clinicians and patient advocates – shared insights to inform educational webinars and podcasts that will be promoted and disseminated across the American Heart Association’s extensive health care professional network. The multidisciplinary group also recommended:

  • development of patient and referring physician tools to drive earlier diagnosis,
  • creation of a care pathway and structures to support safe extraction, and
  • the launch of patient awareness and education campaign.


“To treat CIED infections well, you need a broad-based, interdisciplinary approach to gather and leverage the available experts,” said Dr. Bruce Wilkoff, MD, planning group chairperson of the Association’s CIED initiative and director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic. “The American Heart Association is the perfect organization to get the message out. We can improve awareness, detection, and treatment of CIED infections if we all work together.”

The Hypertrophic Cardiomyopathy Association recognizes the importance of monitoring patient health, especially post-implantation, and being alert to the potential for infection.


Learn more about this effort to drive evidence-based, equitable CIED infection care and sign up to receive the summit report and access related educational resources at www.heart.org/treat2beatciedinfection.

HCMA Blog

April 30, 2025
Medical Management means using medicines and other non-invasive therapies to relieve symptoms. It's exciting that new treatments for HCM are being studied and that the FDA approved Camzyos in 2022! HCM can cause various symptoms depending on how stiff the heart is, how much scarring (fibrosis) there is, and whether there is obstruction. Some people have no noticeable symptoms. Common symptoms are chest pain/pressure, shortness of breath, lightheadedness, fatigue, palpitations, and brain fog. Syncope (fainting) is dramatic but not as common as the other symptoms. Medications are the first-line treatment for symptoms of HCM. If patients can't take one class of medication, they can try a medication from a different class. Here are some medications used to treat HCM and what they're for: Beta Blockers - make your heart beat slower and relax better. They allow the heart to fill more completely between beats. They can lower blood pressure and relieve symptoms. Calcium Channel Blockers - used to lower blood pressure and slow the heart rate. May reduce symptoms from obstruction in HCM. Myosin Inhibitors - cause the heart to beat with less force. They may reduce obstruction and septal thickness in some patients. Camzyos (mavacamten) is the first of this class of medication. For more information, click HERE . Antiarrhythmics - help to restore normal rhythm in the heart. Blood Thinners - anticoagulants and anti-platelets make it harder for blood to clot. They are prescribed to reduce the risk of stroke. This risk is higher in patients with afib, aflutter, and artificial heart valves. Diuretics , or "water pills," help the kidneys get rid of extra water and salt, reducing swelling in the body. Sodium Channel Blockers - may reduce gradient in obstructive HCM and can treat chest pain. Some also act as antiarrhythmics. Antibiotics - treat or prevent bacterial infections. In HCM, they may be given before dental work to prevent infective endocarditis. To learn more and see the side effects of these medications, click HERE .
On a green background, a line drawing of a head that has complicated arrows pointing outwards
By Gordon Fox April 25, 2025
Part 2 of a series on making decisions in HCM. A key reason is that decision making is so difficult is that most decisions involve more than one risk.
Hypertrophic Obsctructive Cardiomyopathy
By Erica Friedman April 22, 2025
Bristol Myers Squibb announces that Camzyos has been approved for Obstructive Hypertrophic Cardiomyopathy in Japan.
More Posts